下尿路症状的医学管理。
Medical management of lower urinary tract symptoms.
作者信息
Laborde Eric E, McVary Kevin T
机构信息
Department of Urology, Northwestern University Feinberg School of Medicine Chicago, IL.
出版信息
Rev Urol. 2009 Fall;11(Suppl 1):S19-25.
Abstract
Lower urinary tract symptoms (LUTS) are a common complaint among aging men and are often caused by benign prostatic hyperplasia (BPH). A number of medical treatments for LUTS/BPH exist, such as alpha-blockers, 5alpha-reductase inhibitors, anticholinergics, phosphodiesterase type 5 (PDE5) inhibitors, and combination therapies. Agonist binding of the alpha(1A)-adrenergic receptor (AR), causing prostatic smooth muscle contraction, has been attributed to cause some LUTS. Therefore, medical therapy has aimed to block the alpha(1A)-AR and improve LUTS. Determining which therapy to choose must take into account individual patient factors as well as cost and patient choice.
摘要
下尿路症状（LUTS）是老年男性的常见主诉，通常由良性前列腺增生（BPH）引起。针对LUTS/BPH有多种医学治疗方法，如α受体阻滞剂、5α还原酶抑制剂、抗胆碱能药物、5型磷酸二酯酶（PDE5）抑制剂以及联合疗法。α（1A）-肾上腺素能受体（AR）的激动剂结合会导致前列腺平滑肌收缩，这被认为是引起一些LUTS的原因。因此，药物治疗旨在阻断α（1A）-AR并改善LUTS。确定选择哪种治疗方法必须考虑个体患者因素以及成本和患者的选择。
相似文献
1
Medical management of lower urinary tract symptoms.下尿路症状的医学管理。
Rev Urol. 2009 Fall;11(Suppl 1):S19-25.
2
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.良性前列腺增生所致下尿路症状与性功能障碍关系的批判性分析。
Eur Urol. 2011 Oct;60(4):809-25. doi: 10.1016/j.eururo.2011.06.037. Epub 2011 Jun 29.
3
Combination therapies for improved management of lower urinary tract symptoms/benign prostatic hyperplasia.用于改善下尿路症状/良性前列腺增生管理的联合疗法。
Drugs Today (Barc). 2016 Sep;52(9):501-517. doi: 10.1358/dot.2016.52.9.2525739.
4
The efficacy of PDE5 inhibitors alone or in combination with alpha-blockers for the treatment of erectile dysfunction and lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis.PDE5 抑制剂单独或联合 α 受体阻滞剂治疗良性前列腺增生所致勃起功能障碍和下尿路症状的疗效：系统评价和荟萃分析。
J Sex Med. 2014 Jun;11(6):1539-45. doi: 10.1111/jsm.12499. Epub 2014 Mar 13.
5
Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?当前下尿路症状/BPH 的医学治疗：我们有标准吗？
Curr Opin Urol. 2014 Jan;24(1):21-8. doi: 10.1097/MOU.0000000000000007.
6
A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.一项关于单独使用磷酸二酯酶 5 抑制剂或与α受体阻滞剂联合治疗良性前列腺增生所致下尿路症状的系统评价和荟萃分析。
Eur Urol. 2012 May;61(5):994-1003. doi: 10.1016/j.eururo.2012.02.033. Epub 2012 Feb 25.
7
Alpha-blockers with or without phosphodiesterase type 5 inhibitor for treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis.α受体阻滞剂联合或不联合磷酸二酯酶 5 抑制剂治疗良性前列腺增生所致下尿路症状：系统评价和荟萃分析。
World J Urol. 2019 Jan;37(1):143-153. doi: 10.1007/s00345-018-2370-z. Epub 2018 Jun 12.
8
Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia.磷酸二酯酶-5 抑制剂与良性前列腺增生。
Curr Opin Urol. 2010 Jan;20(1):49-54. doi: 10.1097/MOU.0b013e328333ac68.
9
[Initial assessment, follow-up and treatment of lower urinary tract symptoms related to benign prostatic hyperplasia: guidelines of the LUTS committee of the French Urological Association].[良性前列腺增生相关下尿路症状的初始评估、随访及治疗：法国泌尿外科学会下尿路症状委员会指南]
Prog Urol. 2012 Dec;22(16):977-88. doi: 10.1016/j.purol.2012.10.001. Epub 2012 Nov 6.
10
Current role for combination therapy in male LUTS.联合治疗在男性下尿路症状中的当前作用。
Arch Esp Urol. 2010 Jun;63(5):323-32.
引用本文的文献
1
Smooth muscle of the lower urinary tract: BK-RyR coupling in physiology and pathophysiology.下尿路平滑肌：生理与病理生理中的BK-RyR偶联
J Muscle Res Cell Motil. 2025 Sep 1. doi: 10.1007/s10974-025-09707-w.
2
Lower urinary tract symptoms (LUTS) and sleep quality: the mediating role of anxiety and depression in middle-aged and older adults from the ardakan cohort study on aging (ACSA).下尿路症状（LUTS）与睡眠质量：来自阿尔达坎衰老队列研究（ACSA）的焦虑和抑郁在中老年人群中的中介作用
BMC Urol. 2025 Jul 4;25(1):157. doi: 10.1186/s12894-025-01835-2.
3
A Rare Case of a Giant Prostatic Urethral Stone and Its Management.一例巨大前列腺尿道结石及其处理的罕见病例
Cureus. 2025 Apr 3;17(4):e81677. doi: 10.7759/cureus.81677. eCollection 2025 Apr.
4
The use of beta-sitosterol for the treatment of prostate cancer and benign prostatic hyperplasia.β-谷甾醇在前列腺癌和良性前列腺增生治疗中的应用。
Am J Clin Exp Urol. 2023 Dec 15;11(6):467-480. eCollection 2023.
5
Prophylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial.预防性使用α受体阻滞剂治疗前列腺癌男性放疗所致下尿路症状：一项III期随机试验
Cancers (Basel). 2023 Jun 30;15(13):3444. doi: 10.3390/cancers15133444.
6
Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size.长期睾酮治疗（TTh）可改善性腺功能低下男性的排尿功能，与前列腺体积无关。
Int Urol Nephrol. 2023 Jul;55(7):1649-1658. doi: 10.1007/s11255-023-03602-4. Epub 2023 May 6.
7
The impact of short term, long term and intermittent infection on male C57BL/6J mouse prostate histology and urinary physiology.短期、长期和间歇性感染对雄性C57BL/6J小鼠前列腺组织学和泌尿生理学的影响。
Am J Clin Exp Urol. 2023 Feb 25;11(1):59-68. eCollection 2023.
8
The IL-4/IL-13 signaling axis promotes prostatic fibrosis.IL-4/IL-13 信号通路促进前列腺纤维化。
PLoS One. 2022 Oct 6;17(10):e0275064. doi: 10.1371/journal.pone.0275064. eCollection 2022.
9
Prostate Transition Zone Fibrosis is Associated with Clinical Progression in the MTOPS Study.前列腺移行带纤维化与 MTOPS 研究中的临床进展相关。
J Urol. 2019 Dec;202(6):1240-1247. doi: 10.1097/JU.0000000000000385. Epub 2019 Jun 12.
10
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.用于治疗与良性前列腺增生相关的下尿路症状的磷酸二酯酶抑制剂。
Cochrane Database Syst Rev. 2018 Nov 16;11(11):CD010060. doi: 10.1002/14651858.CD010060.pub2.
本文引用的文献
1
Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies.高选择性α1A肾上腺素能受体拮抗剂西洛多辛对有良性前列腺增生体征和症状男性的快速疗效：两项3期研究的汇总结果
J Urol. 2009 Jun;181(6):2634-40. doi: 10.1016/j.juro.2009.02.034. Epub 2009 Apr 16.
2
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms.α1肾上腺素能受体亚型与下尿路症状
Int J Urol. 2008 Mar;15(3):193-9. doi: 10.1111/j.1442-2042.2007.01956.x.
3
Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.用于治疗与良性前列腺增生相关的下尿路症状的抗胆碱能疗法。
Pharmacotherapy. 2008 Mar;28(3):356-65. doi: 10.1592/phco.28.3.356.
4
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia.他达拉非可缓解良性前列腺增生继发的下尿路症状。
J Urol. 2007 Apr;177(4):1401-7. doi: 10.1016/j.juro.2006.11.037.
5
6
Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial.枸橼酸西地那非可改善伴有良性前列腺增生相关勃起功能障碍和下尿路症状男性的勃起功能及尿路症状：一项随机双盲试验。
J Urol. 2007 Mar;177(3):1071-7. doi: 10.1016/j.juro.2006.10.055.
7
Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction.阿夫唑嗪与西地那非联合治疗在改善下尿路症状和勃起功能障碍方面优于单一疗法。
Eur Urol. 2007 Jun;51(6):1717-23. doi: 10.1016/j.eururo.2007.01.033. Epub 2007 Jan 16.
8
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.托特罗定与坦索罗辛治疗男性下尿路症状合并膀胱过度活动症：一项随机对照试验。
JAMA. 2006 Nov 15;296(19):2319-28. doi: 10.1001/jama.296.19.2319.
9
The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis.抗胆碱能药物在提示良性前列腺增生的下尿路症状男性中的作用：一项系统评价和荟萃分析。
BJU Int. 2007 Jan;99(1):85-96. doi: 10.1111/j.1464-410X.2006.06574.x. Epub 2006 Oct 9.
10
Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction.托特罗定治疗膀胱出口梗阻男性膀胱过度活动症的安全性和耐受性。
J Urol. 2006 Mar;175(3 Pt 1):999-1004; discussion 1004. doi: 10.1016/S0022-5347(05)00483-0.
Zotero 插件